Breaking News Instant updates and real-time market news.

ADAP

Adaptimmune

$6.56

-0.09 (-1.35%)

09:29
10/12/16
10/12
09:29
10/12/16
09:29

Adaptimmune provides update in NY-ESO SPEAR clinical study

Adaptimmune Therapeutics announced that its amended protocol using its NY-ESO SPEAR, or Specific Peptide Enhanced Affinity Receptor, T-cell therapy in ovarian cancer patients with treatment resistant or refractory metastatic ovarian cancer is now actively recruiting. To date, no objective clinical responses have been reported in the ovarian cancer patients who received NY-ESO SPEAR T-cell therapy in the initial iteration of this trial. Of note, these initial patients received a preconditioning regimen which consisted of cyclophosphamide alone, rather than including fludarabine. Data from Adaptimmune's studies of its NY-ESO SPEAR T-cell therapy in synovial sarcoma patients have indicated the importance of including fludarabine in the preconditioning regimen. The use of fludarabine appears to be required for expansion, response and persistence of transduced cells. As a result, this trial will enroll patients under a revised protocol including a pre-conditioning regimen that includes fludarabine in combination with cyclophosphamide.

ADAP Adaptimmune
$6.56

-0.09 (-1.35%)

02/25/16
02/25/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Boston Scientific (BSX) initiated with a Buy at SunTrust by analyst Bruce Nudell, who expects an organic growth accelerating through 2018 driven by structural heart sales and core market stabilization. 2. Kite Pharma (KITE) initiated with a Buy, with analyst Robyn Karnauskas saying that Kite's technology could be the first to market and its data in the largest blood cancer market look similar to competition. The analyst also started Juno Therapeutics (JUNO) and Adaptimmune (ADAP) with Buy ratings. 3. Insulet (PODD) initiated with a Sell at Empire by analyst Cathy Reese, who said the company has several issues with its OmniPod System that will not be remedied with planned upgrades. 4. Biogen (BIIB) initiated with a Buy at Citi. 5. Crown Castle (CCI) initiated with a Buy at SunTrust. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/04/16
LEER
08/04/16
NO CHANGE
LEER
Outperform
Adaptimmune partial clinical hold on planned trial 'surprising,' says Leerink
Leerink analyst Michael Schmidt sees the announced partial clinical hold on Adaptimmune's liposarcoma study as "surprising" and notes that it introduces some additional risk. However, the analyst says the news does not "fundamentally" change his investment thesis on Adaptimmune as he expects a rapid resolution. Schmidt reiterates an Outperform rating on the shares.
08/26/16
SBSH
08/26/16
NO CHANGE
SBSH
Buy
Adaptimmune partial clinical hold may be lifted within weeks, says Citi
Citi analyst Robyn Karnauskas said that after traveling with several members of Adaptimmune's management team, including its CEO and CFO, she came away feeling that their TCR platform remains in the lead despite delays. The FDA's partial clinical hold in myxoid round cell liposarcoma, or MRCLS, was not related to safety or efficacy of the product and Karnauskas sees the potential for the FDA to possibly reverse the partial clinical hold within a few weeks, she tells investors. Citi keeps a Buy rating on Adaptimmune shares.
09/30/16
RAJA
09/30/16
INITIATION
Target $16
RAJA
Outperform
Adaptimmune initiated with an Outperform at Raymond James
Raymond James analyst Reni Benjamin initiated Adaptimmune with a Buy and a $16 price target saying it is a leading player in the engineered T cell receptor therapy space, with a growing product portfolio concentrating primarily in the solid tumor market.

TODAY'S FREE FLY STORIES

UA

Under Armour

$18.14

0.17 (0.95%)

, UAA

Under Armour

$19.71

0.18 (0.92%)

06:58
04/27/17
04/27
06:58
04/27/17
06:58
Earnings
Under Armour reports Q1 EPS (1c), consensus (4c) »

Reports Q1 revenue…

UA

Under Armour

$18.14

0.17 (0.95%)

UAA

Under Armour

$19.71

0.18 (0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

LLL

L3 Technologies

$171.76

1.3 (0.76%)

06:57
04/27/17
04/27
06:57
04/27/17
06:57
Earnings
L3 Technologies raises FY17 EPS view to $8.50-$8.70 from $8.40-$8.60 »

FY17 consensus $8.60.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

JCI

Johnson Controls

$43.05

-0.15 (-0.35%)

06:57
04/27/17
04/27
06:57
04/27/17
06:57
Earnings
Breaking Earnings news story on Johnson Controls »

Johnson Controls sees Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

AB

AllianceBernstein

$22.75

-0.05 (-0.22%)

06:57
04/27/17
04/27
06:57
04/27/17
06:57
Earnings
AllianceBernstein reports Q1 EPS 46c, consensus 44c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

WEX

WEX

$106.85

0.83 (0.78%)

06:57
04/27/17
04/27
06:57
04/27/17
06:57
Earnings
WEX sees Q2 adjusted EPS $1.19-$1.26, consensus $1.30 »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

JCI

Johnson Controls

$43.05

-0.15 (-0.35%)

06:56
04/27/17
04/27
06:56
04/27/17
06:56
Earnings
Johnson Controls reports Q2 adj. EPS 49c, consensus 49c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

AZN

AstraZeneca

$30.58

0.09 (0.30%)

06:56
04/27/17
04/27
06:56
04/27/17
06:56
Earnings
AstraZeneca confirms FY17 core EPS to decline low to mid teens percentage »

Backs FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 26

    Jun

WEX

WEX

$106.85

0.83 (0.78%)

06:56
04/27/17
04/27
06:56
04/27/17
06:56
Earnings
WEX sees FY17 adjusted EPS $5.15-$5.50, consensus $5.33 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

LLL

L3 Technologies

$171.76

1.3 (0.76%)

06:55
04/27/17
04/27
06:55
04/27/17
06:55
Hot Stocks
Breaking Hot Stocks news story on L3 Technologies »

L3 Technologies raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

PSTB

Park Sterling Bank

$12.52

0.23 (1.87%)

06:55
04/27/17
04/27
06:55
04/27/17
06:55
Hot Stocks
Breaking Hot Stocks news story on Park Sterling Bank »

Park Sterling Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 15

    May

  • 25

    May

LLL

L3 Technologies

$171.76

1.3 (0.76%)

06:55
04/27/17
04/27
06:55
04/27/17
06:55
Earnings
L3 Technologies reports Q1 diluted cont ops EPS $2.07, consensus $1.81 »

Reports Q1 revenue $2.7B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

WEX

WEX

$106.85

0.83 (0.78%)

06:55
04/27/17
04/27
06:55
04/27/17
06:55
Earnings
WEX reports Q1 adjusted EPS $1.23, consensus $1.22 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

AZN

AstraZeneca

$30.58

0.09 (0.30%)

06:54
04/27/17
04/27
06:54
04/27/17
06:54
Earnings
AstraZeneca reports Q1 core EPS 99c vs. 95c last year »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 26

    Jun

STAY

Extended Stay America

$17.45

0.26 (1.51%)

06:54
04/27/17
04/27
06:54
04/27/17
06:54
Earnings
Extended Stay lifts FY17 revenue view to $1.29B-$1.31B from $1.28B-$1.305B 

Consensus $1.3B.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

NTDOY

Nintendo

$31.05

-0.6 (-1.90%)

06:54
04/27/17
04/27
06:54
04/27/17
06:54
Hot Stocks
Breaking Hot Stocks news story on Nintendo »

Nintendo sees FY17 net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOK

Nokia

$5.37

-0.06 (-1.11%)

06:53
04/27/17
04/27
06:53
04/27/17
06:53
Technical Analysis
Nokia trades sharply higher after results »

In the pre-market the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

NTDOY

Nintendo

$31.05

-0.6 (-1.90%)

06:53
04/27/17
04/27
06:53
04/27/17
06:53
Hot Stocks
Nintendo says Switch 'off to a promising start' »

Nintendo Switch, a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQGP

EQT GP

$26.75

-0.39 (-1.44%)

06:52
04/27/17
04/27
06:52
04/27/17
06:52
Hot Stocks
EQT GP increases quarterly distribution 8% to 19.1c per share »

The distribution will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    May

POL

PolyOne

$37.39

-0.02 (-0.05%)

06:51
04/27/17
04/27
06:51
04/27/17
06:51
Earnings
PolyOne reports Q1 adjusted EPS 59c, consensus 54c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 11

    May

STAY

Extended Stay America

$17.45

0.26 (1.51%)

06:51
04/27/17
04/27
06:51
04/27/17
06:51
Earnings
Extended Stay America reports Q1 adj. EPS 15c, consensus 12c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

FCAU

Fiat Chrysler

$11.65

1.11 (10.53%)

, GOOG

Alphabet

$871.73

-0.57 (-0.07%)

06:51
04/27/17
04/27
06:51
04/27/17
06:51
Periodicals
Fiat Chrysler seeks more self-driving supplier partners, Reuters reports »

Fiat Chrysler (FCAU) is…

FCAU

Fiat Chrysler

$11.65

1.11 (10.53%)

GOOG

Alphabet

$871.73

-0.57 (-0.07%)

GOOGL

Alphabet Class A

$889.14

0.3 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 16

    May

  • 22

    May

NTDOY

Nintendo

$31.05

-0.6 (-1.90%)

06:51
04/27/17
04/27
06:51
04/27/17
06:51
Earnings
Nintendo reports FY16 profit per share Y853.87 vs. Y137.4 last year »

Reports FY16 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

06:50
04/27/17
04/27
06:50
04/27/17
06:50
General news
Front-month WTI crude prices are down 1% »

Front-month WTI crude…

EXAS

Exact Sciences

$23.80

-1.09 (-4.38%)

06:50
04/27/17
04/27
06:50
04/27/17
06:50
Technical Analysis
Exact Sciences hits new 52-week high after results »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 30

    May

  • 06

    Jun

BWA

BorgWarner

$41.06

0.22 (0.54%)

06:49
04/27/17
04/27
06:49
04/27/17
06:49
Earnings
BorgWarner now sees FY17 EPS $3.50-$3.60, consensus $3.41 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.